ArticleInternal medicine (Tokyo, Japan)2017

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.

Kazuhiko Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.